RE:RE:RE:RE:exel panc phase 3 study stopped and unblinded earlyNow I can see why you posted that information. It really does confirm Notable's claim that companies can get leap forward without the need to get to the finish line with Phase 3 testing.
Fingers crossed.
itntdf wrote: believe notable addressed part of your questions. my point in posting this was to pony onto some of notable's recent posts addressing the pathway forward and the possibility of outstanding results in an area where there are few to none options for treatment that oncy could advance one of their fast tracks without the need to finish a phase 3.
we certainly have not lost the race and at any rate we were not in a race with exel.
on the downside, we won't have a registration trial until around the middle of 2024. we could, however, have our pre-registration trial stopped with eye-opening results and maybe get that approval to market and move into a phase 4 bypassing some or all of a phase 3.
hope springs eternal but some of us don't have an eternity to wait.
results will move the needle and i don't mean murine results.